Literature DB >> 8916918

Identification of gamma-endorphin-generating enzyme as insulin-degrading enzyme.

A Safavi1, B C Miller, L Cottam, L B Hersh.   

Abstract

The EL-4 thymoma cell line contains a peptidase which converts beta-endorphin to beta-endorphin 1-17 (gamma-endorphin), beta-endorphin 1-18, and their corresponding C-terminal fragments. This enzyme was purified approximately 700-fold to a single band on an SDS-polyacrylamide gel (106 kDa) in 16% yield. Estimation of the native molecular weight by molecular sieve chromatography gave a value of approximately 220 kDa, indicating that this enzyme is a dimer. Peptide sequencing demonstrated this activity can be attributed to insulin degrading enzyme, a previously described member of the inverzincin family (Hooper, 1994). Kinetic studies with a number of peptide substrates indicate that the enzyme preferentially cleaves on the amino side of hydrophobic or basic residues. However, the substrate specificity is more complex since not all basic and hydrophobic residues in a peptide are cleaved. The enzyme exhibits a requirement for a P'2 residue. On the basis of kcat/K(m) values, insulin, growth hormone releasing factor, and beta-endorphin are nearly equivalent substrates for the enzyme; however, growth hormone releasing factor and beta-endorphin exhibit a 40-fold higher kcat, but a 10-fold decreased affinity relative to insulin. A role for insulin-degrading enzyme as both a beta-endorphin-processing and -inactivating enzyme is implicated from these studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8916918     DOI: 10.1021/bi960582q

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  28 in total

1.  Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization.

Authors:  V Chesneau; K Vekrellis; M R Rosner; D J Selkoe
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

2.  Toxoplasma gondii toxolysin 4 is an extensively processed putative metalloproteinase secreted from micronemes.

Authors:  Julie Laliberté; Vern B Carruthers
Journal:  Mol Biochem Parasitol       Date:  2011-01-26       Impact factor: 1.759

3.  An angiotensin-(1-7) peptidase in the kidney cortex, proximal tubules, and human HK-2 epithelial cells that is distinct from insulin-degrading enzyme.

Authors:  Bryan A Wilson; Nildris Cruz-Diaz; Allyson C Marshall; Nancy T Pirro; Yixin Su; TanYa M Gwathmey; James C Rose; Mark C Chappell
Journal:  Am J Physiol Renal Physiol       Date:  2015-01-07

4.  Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques.

Authors:  A Mukherjee; E Song; M Kihiko-Ehmann; J P Goodman; J S Pyrek; S Estus; L B Hersh
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

5.  Production of an antigenic peptide by insulin-degrading enzyme.

Authors:  Nicolas Parmentier; Vincent Stroobant; Didier Colau; Philippe de Diesbach; Sandra Morel; Jacques Chapiro; Peter van Endert; Benoît J Van den Eynde
Journal:  Nat Immunol       Date:  2010-04-04       Impact factor: 25.606

6.  Mixed dimers of insulin-degrading enzyme reveal a cis activation mechanism.

Authors:  Eun Suk Song; David W Rodgers; Louis B Hersh
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

7.  Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo.

Authors:  Bonnie C Miller; Elizabeth A Eckman; Kumar Sambamurti; Nicole Dobbs; K Martin Chow; Christopher B Eckman; Louis B Hersh; Dwain L Thiele
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

8.  In vitro degradation of insulin-like peptide 3 by insulin-degrading enzyme.

Authors:  Wei-Jie Zhang; Xiao Luo; Zhan-Yun Guo
Journal:  Protein J       Date:  2010-02       Impact factor: 2.371

9.  Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme.

Authors:  Enrico Malito; Luis A Ralat; Marika Manolopoulou; Julie L Tsay; Natasha L Wadlington; Wei-Jen Tang
Journal:  Biochemistry       Date:  2008-12-02       Impact factor: 3.162

10.  Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin.

Authors:  Malcolm A Leissring; Enrico Malito; Sabrine Hedouin; Lael Reinstatler; Tomoko Sahara; Samer O Abdul-Hay; Shakeel Choudhry; Ghulam M Maharvi; Abdul H Fauq; Malwina Huzarska; Philip S May; Sungwoon Choi; Todd P Logan; Benjamin E Turk; Lewis C Cantley; Marika Manolopoulou; Wei-Jen Tang; Ross L Stein; Gregory D Cuny; Dennis J Selkoe
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.